The Modified Hodge Test (MHT): A Phenotypic Assay for Carbapenemase Detection
The Modified Hodge Test (MHT), often referred to as the cloverleaf test, is a classic phenotypic microbiological assay that has been extensively used in clinical laboratories for the detection of carbapenemase activity in Gram-negative bacteria, particularly members of the Enterobacteriaceae family. Carbapenemases are a group of β-lactamase enzymes that are capable of hydrolyzing and inactivating carbapenem antibiotics (such as meropenem, imipenem, and ertapenem), which are often considered the last-resort class of drugs for treating severe infections caused by multi-drug resistant (MDR) organisms. The emergence and global dissemination of carbapenemase-producing organisms, such as those harboring Klebsiella pneumoniae Carbapenemase (KPC), New Delhi Metallo-β-lactamase (NDM), or OXA-48 type enzymes, represent a critical public health threat. As such, the timely and accurate screening for these resistance mechanisms is indispensable for guiding appropriate antimicrobial therapy, implementing effective infection control measures, and monitoring epidemiological spread. Although the MHT has been largely superseded by newer, more rapid, and more specific assays like the Modified Carbapenem Inactivation Method (mCIM) in official guidelines, its simplicity and low cost have ensured its continued use as a foundational screening tool in many resource-limited settings worldwide.
Principle of Carbapenemase Detection by MHT
The principle of the Modified Hodge Test is elegantly simple, relying on the diffusion of an active carbapenem antibiotic through agar and the subsequent enzymatic degradation of that antibiotic by the test organism. The test is performed on Mueller-Hinton Agar (MHA) and involves three main components: a carbapenem antibiotic disk, a carbapenem-susceptible indicator organism, and the test organism being evaluated for carbapenemase production. The standard indicator strain used is a known carbapenem-susceptible strain of *Escherichia coli* (most commonly *E. coli* ATCC 25922), which is spread over the plate to create a continuous lawn of growth.
When a carbapenem-containing disk is placed on this lawn, the antibiotic diffuses into the agar, inhibiting the growth of the susceptible *E. coli* and creating a clear zone of inhibition. The test organism is then streaked in a straight line from the edge of the carbapenem disk toward the edge of the plate. If the test organism produces a carbapenemase enzyme, the enzyme diffuses into the agar surrounding the streak line. As the enzyme hydrolyzes the carbapenem, the local concentration of the active antibiotic drops significantly. This enzymatic inactivation allows the adjacent carbapenem-susceptible *E. coli* indicator strain to “rescue” its growth, extending or creeping toward the antibiotic disk along the streak of the test organism. This enhanced growth pattern creates a distinct, recognizable clover leaf-like indentation where the two organisms intersect, which signifies a positive MHT result.
Key Requirements and Step-by-Step Procedure
Performing the Modified Hodge Test requires standard microbiology laboratory materials and a meticulous adherence to the standardized protocol to ensure reliable results. The required components include Mueller-Hinton Agar (MHA) plates, a 10 µg meropenem or ertapenem susceptibility disk, the carbapenem-susceptible indicator strain (*E. coli* ATCC 25922), the test organism, sterile saline or broth, and 0.5 McFarland turbidity standards.
The procedure generally follows these steps:
- **Preparation of Indicator Lawn:** Prepare a bacterial suspension of the *E. coli* ATCC 25922 indicator strain adjusted to a 0.5 McFarland standard. This suspension is then diluted 1:10 (e.g., 0.5 mL of the 0.5 McFarland suspension mixed with 4.5 mL of broth or saline). This final diluted suspension is streaked or spread uniformly onto the entire MHA plate to create a background lawn and allowed to dry for 3-10 minutes.
- **Disk Placement:** A single 10 µg meropenem or ertapenem disk is placed aseptically at the center of the inoculated test area.
- **Inoculation of Test Organism:** The test organism (the potential carbapenemase producer) is then streaked in a straight line from the edge of the antibiotic disk outwards to the edge of the plate. Up to four different test organisms can often be tested on a single standard MHA plate.
- **Incubation:** The plate is incubated overnight at 35°C $pm$ 2°C in ambient air for 16-24 hours. The duration is critical, as a full incubation period is necessary for the enzyme activity and subsequent indicator strain growth to become visible.
Interpretation of Results and Clinical Significance
The plate is examined for enhanced growth of the *E. coli* indicator strain at the intersection of the test organism streak and the zone of inhibition. A clear **Positive MHT result** is defined by a clover leaf-like indentation of the *E. coli* growing along the streak of the test organism within the zone of inhibition. This pattern unequivocally demonstrates that the test isolate has produced a carbapenemase enzyme that inactivated the meropenem or ertapenem in that localized area, thereby “rescuing” the susceptible indicator strain. A **Negative MHT result** shows no enhanced growth or indentation along the test organism’s streak, indicating that the isolate is not producing a carbapenemase enzyme that can effectively hydrolyze the carbapenem.
A positive result provides crucial information that the carbapenem resistance observed in the isolate is mediated by a carbapenemase, which has profound implications for treatment decisions and infection control. For instance, the MHT has been shown to be particularly reliable for detecting Klebsiella pneumoniae Carbapenemase (KPC) enzymes. While newer tests are now recommended for primary screening, the MHT’s initial use as a definitive phenotypic test for carbapenemase production allowed clinical laboratories to quickly flag and manage these highly resistant pathogens, significantly contributing to global efforts to control their spread.
Limitations and the Evolution of Carbapenemase Testing
Despite its advantages in simplicity and cost, the Modified Hodge Test has significant limitations that have prompted the development of alternative methods. The MHT’s primary drawback is its compromised sensitivity for certain carbapenemase classes, most notably the Metallo-β-Lactamases (MBLs), such as NDM-1 and VIM-type enzymes. For NDM-1 producers, which can be anchored to the bacterial outer membrane, the enzyme may not diffuse effectively into the agar, leading to false-negative MHT results. Research has shown this false negativity can be mitigated by modifications, such as the addition of the nonionic surfactant Triton X-100 to the agar, a technique known as the Triton Hodge Test (THT).
Furthermore, the MHT suffers from limited specificity. It is prone to giving false-positive results when testing isolates that produce Extended-Spectrum β-Lactamases (ESBLs) or AmpC cephalosporinases in combination with a permeability defect (e.g., loss of porins). This combination of resistance mechanisms can distort the zone of inhibition enough to mimic a positive result, leading to misclassification. The subjective nature of interpreting the ‘clover leaf’ indentation and the requirement for an overnight incubation period also represent practical disadvantages. Consequently, the Clinical and Laboratory Standards Institute (CLSI) has officially replaced the MHT with the Modified Carbapenem Inactivation Method (mCIM) and the EDTA-Modified Carbapenem Inactivation Method (eCIM) as the recommended phenotypic tests, as these newer assays are faster, less subjective, and have improved sensitivity across a wider range of carbapenemases.
In summary, the Modified Hodge Test remains a historically and pedagogically significant tool in microbiology. It effectively demonstrates the powerful concept of enzymatic carbapenem hydrolysis, even as more advanced molecular and colorimetric methods continue to emerge as the clinical standard for combatting the ongoing threat of carbapenemase-producing organisms.